{"id":26949,"date":"2023-02-24T15:47:26","date_gmt":"2023-02-24T12:47:26","guid":{"rendered":"https:\/\/w3.bilkent.edu.tr\/tr\/?page_id=26949"},"modified":"2023-03-03T17:01:47","modified_gmt":"2023-03-03T14:01:47","slug":"selim-giray-man99","status":"publish","type":"page","link":"https:\/\/w3.bilkent.edu.tr\/tr\/selim-giray-man99\/","title":{"rendered":"GlaxoSmithKline T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Selim Giray MAN\u201999"},"content":{"rendered":"

(Dergi Bilkent\u00a034. say\u0131 \u2013 Aral\u0131k 2020)<\/p>\n

 <\/p>\n

\"\"<\/a><\/strong>GlaxoSmithKline T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Selim Giray (\u0130\u015fletme 1999) ile yakla\u015f\u0131k 20 y\u0131ld\u0131r \u00e7al\u0131\u015ft\u0131\u011f\u0131 ila\u00e7 end\u00fcstrisini konu\u015ftuk.<\/h3>\n

– LinkedIn Profili<\/a><\/p>\n

 <\/p>\n

Bilkent \u00f6ncesinde ve sonras\u0131nda hangi okullarda e\u011fitim ald\u0131n\u0131z?<\/strong><\/p>\n

Ortaokul ve lise e\u011fitimimi Robert Kolej\u2019de tamamlad\u0131m. Bilgi \u00dcniversitesi\u2019nden MBA diplomas\u0131na de sahibim.<\/p>\n

\u0130lk i\u015finiz hangi sekt\u00f6rdeydi?<\/strong><\/p>\n

Akaryak\u0131t sekt\u00f6r\u00fcnde bir y\u0131ll\u0131k sat\u0131\u015f temsilcili\u011fi deneyimim oldu. Ard\u0131ndan ila\u00e7 sekt\u00f6r\u00fcne ge\u00e7tim.<\/p>\n

\u0130la\u00e7 end\u00fcstrisi bilin\u00e7li bir se\u00e7im miydi, yoksa \u015fans eseri yakalad\u0131\u011f\u0131n\u0131z bir f\u0131rsat m\u0131yd\u0131?<\/strong><\/p>\n

G\u00f6r\u00fc\u015flerini \u00f6nemsedi\u011fim b\u00fcy\u00fcklerimin y\u00f6nlendirmesiyle yapt\u0131\u011f\u0131m bir tercihti; ancak sonras\u0131nda g\u00f6rd\u00fcm ki \u00e7ok do\u011fru bir karar vermi\u015fim. \u0130la\u00e7 end\u00fcstrisi, bilim ve teknolojinin i\u00e7 i\u00e7e ge\u00e7ti\u011fi, topluma katk\u0131s\u0131 \u00e7ok y\u00fcksek olan, dinamik bir sekt\u00f6rd\u00fcr.<\/p>\n

\u0130nsanlar\u0131n daha sa\u011fl\u0131kl\u0131 ve uzun bir ya\u015fam s\u00fcrmelerini ama\u00e7 edinen bir sekt\u00f6rde \u00e7al\u0131\u015fman\u0131n motivasyonu da, sorumlulu\u011fu da \u00e7ok b\u00fcy\u00fck.<\/p>\n

\u00c7al\u0131\u015ft\u0131\u011f\u0131n\u0131z \u015firketleri ve y\u00fcr\u00fctt\u00fc\u011f\u00fcn\u00fcz g\u00f6revleri \u00f6\u011frenebilir miyiz?<\/strong><\/p>\n

Sekt\u00f6rdeki kariyerime Roche b\u00fcnyesinde ba\u015flad\u0131m. Sonras\u0131nda MSD\u2019de \u00fcr\u00fcn m\u00fcd\u00fcr\u00fc, merkez ve Do\u011fu Avrupa \u00fclkelerinden sorumlu b\u00f6lge pazarlama m\u00fcd\u00fcr\u00fc, ulusal sat\u0131\u015f direkt\u00f6r\u00fc gibi pozisyonlarda g\u00f6rev ald\u0131m. 2010 – 2012 y\u0131llar\u0131 aras\u0131nda Cenovapharma\u2019da genel m\u00fcd\u00fcr olarak g\u00f6rev yapt\u0131m.<\/p>\n

2014\u2019te i\u015f birimi direkt\u00f6r\u00fc unvan\u0131yla GSK ekibine kat\u0131ld\u0131m. Ocak 2016\u2019da CEO Gelece\u011fin Stratejisi Grubu\u2019na kat\u0131larak Londra\u2019daki GSK genel merkezinde \u00e7al\u0131\u015ft\u0131m. 2016 – 2018 y\u0131llar\u0131 aras\u0131nda Allergan \u0130la\u00e7lar\u0131 genel m\u00fcd\u00fcrl\u00fc\u011f\u00fc g\u00f6revini icra ettim. Ocak 2018\u2019de ise GSK T\u00fcrkiye ailesine geri d\u00f6nd\u00fcm ve GSK T\u00fcrkiye genel m\u00fcd\u00fcr\u00fc olarak g\u00f6rev yapmaya ba\u015flad\u0131m.<\/p>\n

\u0130la\u00e7 end\u00fcstrisi deyince akla ilk saha sat\u0131\u015f ekipleri gelebiliyor. Sekt\u00f6r\u00fcn\u00fczde hangi disiplinler i\u00e7in kariyer f\u0131rsatlar\u0131 var?<\/strong><\/p>\n

\u0130la\u00e7 end\u00fcstrisi pek \u00e7ok disiplini i\u00e7inde bar\u0131nd\u0131ran, b\u00fcy\u00fck bir yap\u0131. Hekimlere ve eczac\u0131lara g\u00fcncel bilgilerin do\u011fru ve zaman\u0131nda ula\u015ft\u0131r\u0131lmas\u0131n\u0131 sa\u011flayan, b\u00f6ylelikle hastalar\u0131n en son tedavi se\u00e7eneklerine eri\u015fmelerine katk\u0131da bulunan saha ekipleri bu yap\u0131n\u0131n \u00f6nemli bir par\u00e7as\u0131. Di\u011fer kurumsal organizasyonlarda oldu\u011fu gibi sa\u011fl\u0131k sekt\u00f6r\u00fcnde de pazarlama, finans, teknoloji, insan kaynaklar\u0131, kurumsal ileti\u015fim gibi pek \u00e7ok birim yer al\u0131yor. Sekt\u00f6r \u00f6zelinde ise ar-ge ve \u00fcretim fonksiyonlar\u0131yla birlikte ruhsatland\u0131rma, kamu ili\u015fkileri gibi farkl\u0131 birimler bulunuyor. Sosyal bilimlerden fen bilimlerine uzanan bir\u00e7ok disiplinden yetene\u011fe kariyer f\u0131rsat\u0131 sunan bir sekt\u00f6rden bahsediyoruz.<\/p>\n

Yeni bir ilac\u0131n ke\u015fif ve geli\u015ftirme a\u015famalar\u0131yla birlikte eczanede raflara girmesi genelde ne kadar s\u00fcrer?<\/strong><\/p>\n

Yeni bir ilac\u0131n raflarda yer alabilmesi i\u00e7in klinik ara\u015ft\u0131rmalarla g\u00fcvenilirli\u011fi ve etkinli\u011finin ispatlanmas\u0131 gerekiyor. Bu da yakla\u015f\u0131k 15-20 y\u0131l alan, pek \u00e7ok faz\u0131 bar\u0131nd\u0131ran bir s\u00fcre\u00e7. \u00dcr\u00fcn piyasaya \u00e7\u0131kt\u0131ktan sonra izleme ve \u00e7al\u0131\u015fma s\u00fcre\u00e7leri de devam eder.<\/p>\n

Bu kadar kapsaml\u0131 bir \u00e7al\u0131\u015fman\u0131n en \u00f6nemli k\u0131sm\u0131, hangi molek\u00fcl i\u00e7in 15-20 y\u0131l emek verilmesinin se\u00e7ilmesi. Y\u00fcksek teknolojiden ve yapay zek\u00e2yla modellenmi\u015f sistemlerden faydalanarak en etkin, en g\u00fcvenli molek\u00fcller \u00fczerinde \u00e7al\u0131\u015f\u0131yor ve hastalar\u0131n sa\u011fl\u0131kl\u0131 ya\u015fam kalitesini art\u0131racak tedaviler geli\u015ftirmeyi hedefliyoruz.<\/p>\n

\u0130la\u00e7 \u00fcreticileri gelirlerinin yakla\u015f\u0131k ne kadar\u0131n\u0131 ar-ge i\u00e7in ay\u0131r\u0131yor?<\/strong><\/p>\n

Ara\u015ft\u0131rma-geli\u015ftirme faaliyetleri, insan sa\u011fl\u0131\u011f\u0131n\u0131 do\u011frudan etkileyen sonu\u00e7lar do\u011furmas\u0131 sebebiyle ila\u00e7 sekt\u00f6r\u00fcnde b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor. Yeni bir tedaviyi insanl\u0131\u011f\u0131n hizmetine sunabilmek, ortalama 12-15 y\u0131l s\u00fcren ve titizlikle y\u00fcr\u00fct\u00fclen bir ar-ge s\u00fcreci gerektiriyor. Bu alandaki yat\u0131r\u0131mlara ayr\u0131lan b\u00fct\u00e7e ise \u015firketlerin stratejileriyle parallel bi\u00e7imde de\u011fi\u015febiliyor.<\/p>\n

\u0130novasyona ve dolay\u0131s\u0131yla ara\u015ft\u0131rmageli\u015ftirmeye verdi\u011fimiz \u00f6nemin bir sonucu olarak 300 y\u0131l\u0131 a\u015fk\u0131n ge\u00e7mi\u015fimize 5 Nobel \u00d6d\u00fcl\u00fc s\u0131\u011fd\u0131rm\u0131\u015f bir \u015firketiz. GSK, sadece ge\u00e7ti\u011fimiz y\u0131l 4,3 milyar sterlin ar-ge b\u00fct\u00e7esi ay\u0131rd\u0131.<\/p>\n

Firmalar aras\u0131nda ar-ge rekabeti hangi \u00e7al\u0131\u015fmalar \u00fczerinde bi\u00e7imleniyor?<\/strong><\/p>\n

G\u00fcn\u00fcm\u00fczde tedavisi bulunamam\u0131\u015f pek \u00e7ok hastal\u0131k var. Bunlar elbette ila\u00e7 end\u00fcstrisinin a\u011f\u0131rl\u0131kl\u0131 yat\u0131r\u0131m yapt\u0131\u011f\u0131 alanlar. \u00dcstelik \u00e7evresel fakt\u00f6rlerin tetikledi\u011fi yeni sa\u011fl\u0131k sorunlar\u0131 da ortaya \u00e7\u0131k\u0131yor. Bunun en yak\u0131n \u00f6rne\u011fini COVID-19 salg\u0131n\u0131nda ya\u015f\u0131yoruz.<\/p>\n

\"\"<\/a>\u015eirketinizdeki \u00e7al\u0131\u015fma ve \u00fcretim ko\u015fullar\u0131 salg\u0131ndan nas\u0131l etkilendi?<\/strong><\/p>\n

Salg\u0131n\u0131 ilk g\u00fcnden itibaren \u00e7ok yak\u0131ndan izledik. Operasyonel s\u00fcre\u00e7leri iyi analiz ederek t\u00fcm senaryolar i\u00e7in planlar\u0131m\u0131z\u0131 haz\u0131rlad\u0131k. \u00d6ncelik ta\u015f\u0131yan iki konumuz vard\u0131. \u0130lki topluma ve hastalara kar\u015f\u0131 olan sorumlulu\u011fumuz \u00e7er\u00e7evesinde ila\u00e7 tedarikinin kesintiye u\u011framamas\u0131 ad\u0131na i\u015f s\u00fcreklili\u011finin sa\u011flanmas\u0131yd\u0131; ikincisi ise \u00e7al\u0131\u015fanlar\u0131m\u0131z\u0131n ve ailelerinin sa\u011fl\u0131\u011f\u0131n\u0131 korumakt\u0131.<\/p>\n

13 Mart\u2019tan itibaren t\u00fcm kadromuzla birlikte evden \u00e7al\u0131\u015fmaya ba\u015flad\u0131k. Saha ekiplerimizin hekim ve eczac\u0131lara yapt\u0131\u011f\u0131 y\u00fcz y\u00fcze tan\u0131t\u0131mlar\u0131 durdurduk; \u00e7evrimi\u00e7i platformlarla uzaktan tan\u0131t\u0131m modeline ge\u00e7tik. Hem \u015firket i\u00e7i operasyonlar\u0131 hem de en \u00f6nemli payda\u015flar\u0131m\u0131z olan sa\u011fl\u0131k profesyonelleriyle ileti\u015fimi dijital ve kesintisiz \u015fekilde s\u00fcrd\u00fcrebildik.<\/p>\n

\u00c7al\u0131\u015fanlar\u0131m\u0131z\u0131 zihnen ve bedenen desteklemek amac\u0131yla haftal\u0131k \u00e7evrimi\u00e7i programlar olu\u015fturduk. Bu programlara aileleriyle birlikte kat\u0131labiliyorlard\u0131. Alan\u0131nda uzman konu\u015fmac\u0131lar\u0131n yer ald\u0131\u011f\u0131 oturumlar, y\u00f6netim ekibiyle kahve sohbetleri, canl\u0131 spor seanslar\u0131, \u00e7ocuklar i\u00e7in etkinlik programlar\u0131 gibi kapsaml\u0131 bir i\u00e7erikle \u00e7al\u0131\u015fanlar\u0131m\u0131za bir\u00e7ok alanda destek vermeye odakland\u0131k.<\/p>\n

Hem hastalara kar\u015f\u0131 sorumlulu\u011fumuz hem de i\u015f s\u00fcre\u00e7leri ve \u00e7al\u0131\u015fan g\u00fcvenli\u011fi a\u00e7\u0131s\u0131ndan bu d\u00f6nemi ba\u015far\u0131yla y\u00f6nettik.<\/p>\n

GSK ve Sanofi, Covid-19 a\u015f\u0131s\u0131 i\u00e7in k\u00fcresel bir i\u015f birli\u011fine gitti. Firman\u0131z\u0131n ve sekt\u00f6r\u00fcn\u00fcz\u00fcn salg\u0131nla m\u00fccadeleye ba\u015fka katk\u0131lar\u0131 var m\u0131?<\/strong><\/p>\n

A\u015f\u0131 ve devam\u0131nda gelecek tedavilerle ilgili \u00e7ok umutlu oldu\u011fumu s\u00f6yleyebilirim. Bu ola\u011fan\u00fcst\u00fc d\u00f6nem, ola\u011fan\u00fcst\u00fc giri\u015fimleri de beraberinde getirdi ve sa\u011fl\u0131k alan\u0131nda \u00e7ok \u00f6nemli i\u015f birlikleri hayata ge\u00e7irilmeye ba\u015fland\u0131. Biz de Sanofi ile a\u015f\u0131 alan\u0131nda g\u00fc\u00e7lerimizi birle\u015ftirdik. Bu \u00e7er\u00e7evede geli\u015ftirilecek a\u015f\u0131 aday\u0131n\u0131n faz 1\/2 klinik denemelerine Eyl\u00fcl 2020\u2019de ba\u015flad\u0131k. Y\u0131l sonu itibar\u0131yla faz 3\u2019e ge\u00e7meyi hedefliyoruz.<\/p>\n

COVID-19 a\u015f\u0131s\u0131 i\u00e7in geli\u015ftirilen bir\u00e7ok i\u015f birli\u011fini destekleyecek 1 milyar doz pandemik a\u015f\u0131 adjuvan\u0131 \u00fcretmeyi planl\u0131yoruz. COVID-19 ve gelecekteki olas\u0131 salg\u0131nlarla m\u00fccadele kapsam\u0131nda Vir Biotechnology ile ar-ge ortakl\u0131\u011f\u0131na gittik. Ekim 2020\u2019de antikor tedavisi i\u00e7in faz 3 \u00e7al\u0131\u015fmalar\u0131na ge\u00e7ildi.<\/p>\n

COVID-19\u2019un d\u00fcnya genelindeki yay\u0131l\u0131m\u0131n\u0131 kontrol alt\u0131na almak amac\u0131yla Birle\u015fmi\u015f Milletler ve D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc taraf\u0131ndan olu\u015fturulan COVID-19 Dayan\u0131\u015fma Fonu\u2019na 10 milyon ABD dolar\u0131 ba\u011f\u0131\u015f yapt\u0131k. T\u00fcrkiye\u2019de ise COVID-19 m\u00fccadelesinde sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 ve hasta faydas\u0131na y\u00f6nelik ekipman tedarikine 1 milyon TL civar\u0131nda deste\u011fimiz oldu.<\/p>\n

K\u00fcresel anlamda ise Salg\u0131na Haz\u0131rl\u0131k \u0130novasyonlar\u0131 Koalisyonu (CEPI) ve COVID-19 Tedavi H\u0131zland\u0131r\u0131c\u0131 ara\u015ft\u0131rma program\u0131yla i\u015f birlikleri yapt\u0131k. Kuzey Amerika, Avrupa ve \u00c7in d\u00e2hil olmak \u00fczere d\u00fcnya \u00e7ap\u0131nda bir\u00e7ok \u015firketle ve ara\u015ft\u0131rma grubuyla a\u015f\u0131 ve ila\u00e7 geli\u015ftirmeye y\u00f6nelik \u00e7al\u0131\u015fmalar ba\u015flatt\u0131k.<\/p>\n

T\u00fcrkiye\u2019deki ilaca ili\u015fkin ar-ge etkinlikleri ve yat\u0131r\u0131m ortam\u0131n\u0131 yorumlayabilir misiniz?<\/strong><\/p>\n

T\u00fcrkiye, ila\u00e7 alan\u0131nda yat\u0131r\u0131m merkezi olabilecek bir potansiyele sahip. Bizim burada \u00fczerimize d\u00fc\u015fen, t\u00fcm payda\u015flarla beraber hasta odakl\u0131, s\u00fcrd\u00fcr\u00fclebilir eri\u015fimi destekleyen bir model olu\u015fturmak. Devletin stratejik \u00f6nceliklerine paralel bir \u015fekilde kamu y\u00f6netimiyle tam bir i\u015f birli\u011fi i\u00e7erisinde ilerlemeye odaklan\u0131yor, t\u00fcm \u00e7al\u0131\u015fmalar\u0131m\u0131zda bu do\u011frultuda hareket ediyoruz.<\/p>\n

GSK \u00fclkemizde ne zamand\u0131r ve hangi alanlarda faaliyet g\u00f6steriyor?<\/strong><\/p>\n

GSK, T\u00fcrkiye\u2019de solunum, a\u015f\u0131, HIV, merkezi sinir sistemi hastal\u0131klar\u0131, dermatoloji, \u00fcroloji, onkoloji ve antiinfektifler odakl\u0131 olmak \u00fczere 8 tedavi alan\u0131nda 61 y\u0131ld\u0131r faaliyet g\u00f6steriyor. T\u00fcrkiye\u2019nin orta vadeli kalk\u0131nma plan\u0131na uygun olarak ihracat ve yerelle\u015fme yat\u0131r\u0131mlar\u0131m\u0131z\u0131 g\u00fc\u00e7lendiriyoruz.<\/p>\n

Hacettepe Teknokent i\u015f birli\u011fiyle hayata ge\u00e7irdi\u011fimiz A\u015f\u0131 Klinik Ara\u015ft\u0131rmalar Merkezi\u2019nde T\u00fcrkiye\u2019deki a\u015f\u0131 klinik ara\u015ft\u0131rmalar\u0131n\u0131n %50\u2019sinden fazlas\u0131n\u0131 y\u00fcr\u00fct\u00fcyoruz. Menenjit, zat\u00fcrre, rotavir\u00fcs, hepatit A, hepatit B, su\u00e7i\u00e7e\u011fi, bo\u011fmaca, k\u0131zam\u0131k, k\u0131zam\u0131k\u00e7\u0131k, kabakulak a\u015f\u0131lar\u0131yla \u00e7ocuklar\u0131n ve yeti\u015fkinlerin sa\u011fl\u0131\u011f\u0131n\u0131 korumak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz.<\/p>\n

Yerelle\u015fme kapsam\u0131nda ger\u00e7ekle\u015ftirdi\u011fimiz 4 yerli \u00fcretim ortakl\u0131\u011f\u0131 var. 30 milyon sterlin \u00f6l\u00e7e\u011finde bir yat\u0131r\u0131mla yerel \u00fcretim oran\u0131m\u0131z\u0131 %62\u2019den %74\u2019e \u00e7\u0131karaca\u011f\u0131z. Bu do\u011frultuda solunum hastal\u0131klar\u0131n\u0131n tedavisinde kullan\u0131lan neb\u00fcl \u00fcr\u00fcnleriyle birlikte HIV tedavisine ili\u015fkin yenilik\u00e7i bir \u00fcr\u00fcn\u00fcn yerel \u00fcretimi i\u00e7in \u00e7al\u0131\u015fmalara devam ediyoruz.<\/p>\n

T\u00fcrkiye, klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131nda GSK\u2019nin \u00f6ncelikli \u00fclkeleri aras\u0131nda. Bug\u00fcn enfeksiyon, onkoloji ve hematoloji ba\u015fta olmak \u00fczere GSK\u2019nin faaliyette bulundu\u011fu t\u00fcm alanlarda ar-ge yat\u0131r\u0131mlar\u0131 a\u00e7\u0131s\u0131ndan ayr\u0131cal\u0131kl\u0131 bir \u00fclke konumunday\u0131z. Bu konum, T\u00fcrkiye\u2019de klinik ara\u015ft\u0131rmalarda yat\u0131r\u0131m ve istihdama da \u00f6nemli bir katk\u0131 sa\u011flayacak.<\/p>\n

Bir \u00fcst d\u00fczey y\u00f6netici bak\u0131\u015f\u0131yla \u00e7al\u0131\u015fanlar\u0131n\u0131zda arad\u0131\u011f\u0131n\u0131z ba\u015fl\u0131ca nitelikleri \u00f6\u011frenebilir miyiz?<\/strong><\/p>\n

\u00c7al\u0131\u015fanlar\u0131n kurum k\u00fclt\u00fcr\u00fcne ve de\u011ferlerine uygun olmas\u0131 \u00f6nceli\u011fimdir. GSK\u2019de d\u00f6rt temel de\u011fer \u00f6ne \u00e7\u0131kar: \u015feffafl\u0131k, insana sayg\u0131, d\u00fcr\u00fcstl\u00fck, hasta odakl\u0131l\u0131k. T\u00fcm s\u00fcre\u00e7lerimizi bu temel \u00fczerine kuruyoruz ve aram\u0131za kat\u0131lacak ekip arkada\u015flar\u0131n\u0131 da bu yap\u0131ya uygun ki\u015filerden se\u00e7iyoruz.<\/p>\n

GSK\u2019nin bir liderden bekledi\u011fi d\u00f6rt davran\u0131\u015f modeli vard\u0131r: \u00f6z sorumluluk, cesaret, ekip \u00e7al\u0131\u015fmas\u0131, geli\u015fim. Sekt\u00f6r\u00fcn dinamik yap\u0131s\u0131n\u0131 ve de\u011fi\u015fimi y\u00f6netebilme konusunda \u00f6ncelik verdi\u011fimiz \u00f6zellikler bunlard\u0131r.<\/p>\n

\"\"<\/a>Bilkent\u2019te ald\u0131\u011f\u0131n\u0131z e\u011fitimin profesyonel ve sosyal hayat\u0131n\u0131za yans\u0131malar\u0131 hakk\u0131nda neler s\u00f6ylemek istersiniz? <\/strong><\/p>\n

\u0130stanbul\u2019da do\u011fdum ve b\u00fcy\u00fcd\u00fcm. Bu nedenle \u00fcniversite e\u011fitimi ailem ve arkada\u015flar\u0131mdan ilk defa uzun s\u00fcreli ayr\u0131 kald\u0131\u011f\u0131m bir d\u00f6nemdi. Ba\u015fta sevdiklerimden uzak olmak ve yaln\u0131zl\u0131k hissiyle biraz zorlanm\u0131\u015ft\u0131m. \u0130ki kentin dinamikleri de ger\u00e7ekten \u00e7ok farkl\u0131; ama d\u00fc\u015f\u00fcnd\u00fc\u011f\u00fcmden \u00e7ok daha \u00e7abuk uyum sa\u011flad\u0131m.<\/p>\n

Farkl\u0131 bir kentte ya\u015faman\u0131n geli\u015fimime katk\u0131s\u0131 \u00e7ok b\u00fcy\u00fck oldu. \u0130nsan\u0131n kendi ayaklar\u0131 \u00fczerinde durabilmesi ve sorumluluk almas\u0131 ba\u015fta \u00f6zg\u00fcven ve cesaretle birlikte pek \u00e7ok \u00f6nemli yetkinli\u011fi de kazanmas\u0131n\u0131 sa\u011fl\u0131yor. Bunun sosyal ve profesyonel hayatta olumlu etkilerini g\u00f6r\u00fcyorum. Kamp\u00fcs hayat\u0131 ise en yak\u0131n dostluklar\u0131n kuruldu\u011fu, bamba\u015fka bir k\u00fclt\u00fcr. Bilkent, \u00f6\u011frencilere sosyal anlamda sundu\u011fu olanaklarla da fark yaratan bir \u00fcniversite diye d\u00fc\u015f\u00fcn\u00fcyorum.<\/p>\n

Bilkent\u2019in \u00e7a\u011f\u0131 yakalayan, teorik bilgilerle s\u0131n\u0131rl\u0131 kalmay\u0131p mesle\u011fin pratiklerini de deneyimleyebilece\u011finiz, yenilik\u00e7i bir e\u011fitim yakla\u015f\u0131m\u0131 var. \u00d6zg\u00fcn ve yarat\u0131c\u0131 d\u00fc\u015f\u00fcnme, do\u011fru analiz etme, ak\u0131lc\u0131 karar verme gibi becerilerinizi geli\u015ftirme imk\u00e2n\u0131 sa\u011flayan, \u00e7ok k\u0131ymetli bir akademik ortama sahip. En \u00f6nemlisi de uluslararas\u0131 d\u00fczeyde bilinirli\u011fi olan bir \u00fcniversiteden mezun olarak profesyonel hayata g\u00fc\u00e7l\u00fc bir ba\u015flang\u0131\u00e7 yapabilmeniz. Kariyerime uluslararas\u0131 ve lider \u015firketlerde ba\u015flamamda Bilkentli olmam\u0131n kayda de\u011fer bir pay\u0131 var.<\/p>\n

Lisans\u00fcst\u00fc derecenizden sonra akademik d\u00fcnyayla etkile\u015fiminiz s\u00fcrd\u00fc m\u00fc? <\/strong><\/p>\n

Ko\u00e7 \u00dcniversitesi\u2019nde kurucusu oldu\u011fum \u0130la\u00e7 Sekt\u00f6r\u00fc \u00dcr\u00fcn M\u00fcd\u00fcr\u00fc Sertifikasyon Program\u0131\u2019nda e\u011fitmenli\u011fe devam ediyorum. \u00dcr\u00fcn m\u00fcd\u00fcrl\u00fc\u011f\u00fc, ila\u00e7 sekt\u00f6r\u00fcn\u00fcn en kritik rollerinden biri. Sekt\u00f6r\u00fcn farkl\u0131 alanlar\u0131nda uzman y\u00f6neticilerin de e\u011fitmen olarak yer ald\u0131\u011f\u0131 program kapsam\u0131nda ila\u00e7 end\u00fcstrisinin yap\u0131s\u0131, mevzuatlar\u0131, i\u015f s\u00fcre\u00e7leri ve payda\u015f ili\u015fkileri gibi pek \u00e7ok ba\u015fl\u0131kla ba\u015far\u0131l\u0131 bir \u00fcr\u00fcn pazarlamas\u0131n\u0131n y\u00f6ntemlerini anlat\u0131yoruz.<\/p>\n

Son olarak hobilerinizi ve \u00f6zel ilgi alanlar\u0131n\u0131z\u0131 soral\u0131m. <\/strong><\/p>\n

Evliyim, iki o\u011flumuz ve 2,5 ya\u015f\u0131nda bir k\u0131z\u0131m\u0131z var. Benim i\u00e7in en b\u00fcy\u00fck keyif ailemle ve de \u00f6zellikle k\u0131z\u0131mla vakit ge\u00e7irmek. Kitap okumak, k\u00fc\u00e7\u00fckl\u00fc\u011f\u00fcmden beri en \u00f6zel ilgi alan\u0131m. Bir de tabii futbol var. Koyu bir Fenerbah\u00e7eli olarak ma\u00e7lar\u0131 olabildi\u011fince takip etmeye \u00e7al\u0131\u015f\u0131r\u0131m.<\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

(Dergi Bilkent\u00a034. say\u0131 \u2013 Aral\u0131k 2020)   GlaxoSmithKline T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Selim Giray (\u0130\u015fletme 1999) ile yakla\u015f\u0131k 20 y\u0131ld\u0131r \u00e7al\u0131\u015ft\u0131\u011f\u0131 ila\u00e7 end\u00fcstrisini konu\u015ftuk. – LinkedIn Profili   Bilkent \u00f6ncesinde ve sonras\u0131nda hangi okullarda e\u011fitim ald\u0131n\u0131z? Ortaokul ve lise e\u011fitimimi Robert Kolej\u2019de tamamlad\u0131m. Bilgi \u00dcniversitesi\u2019nden MBA diplomas\u0131na de sahibim. \u0130lk i\u015finiz [\u2026] <\/p>\n

<\/div>\n

Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/template-full-width.php","meta":{"footnotes":""},"class_list":["post-26949","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/pages\/26949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/comments?post=26949"}],"version-history":[{"count":7,"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/pages\/26949\/revisions"}],"predecessor-version":[{"id":27066,"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/pages\/26949\/revisions\/27066"}],"wp:attachment":[{"href":"https:\/\/w3.bilkent.edu.tr\/tr\/wp-json\/wp\/v2\/media?parent=26949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}